Susan Eliazer

USPTO Granted Patents = 12 (Patent Applications = 7)

CIPO Patents = 9

EPO Patents = 7 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 6

Forward Citations = 327(Granted Patents)

Location History:

San Diego, CA (US) (2009 - 2016)
Moraga, CA (US) (2019 - 2023)

Company Filing History:

Years Active: 2009-2023

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11746323 - PDX1 positive foregut endoderm cells and methods of production (2023-09-05),

2. 11667889 - Methods of making human primitive ectoderm cells (2023-06-06),

3. 11427805 - Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm (2022-08-30),

4. 10550367 - Methods of making human primitive ectoderm cells (2020-02-04),

5. 10465162 - Anterior endoderm cells and methods of production (2019-11-05),

6. 10179902 - Methods of making human primitive ectoderm cells (2019-01-15),

7. 9499795 - PDX1-expressing dorsal and ventral foregut endoderm (2016-11-22),

8. 9222069 - Methods for making anterior foregut endoderm (2015-12-29),

9. 8647873 - PDX1 expressing endoderm (2014-02-11),

10. 8633024 - PDX1 expressing endoderm (2014-01-21),

11. 8216836 - Methods for identifying factors for differentiating definitive endoderm (2012-07-10),

12. 7541185 - Methods for identifying factors for differentiating definitive endoderm (2009-06-02),

Title: The Innovative Contributions of Susan Eliazer

Introduction

Susan Eliazer, an accomplished inventor based in San Diego, California, has made significant strides in the field of cellular biology. With a portfolio of 12 patents, she has played a pivotal role in advancing research related to endoderm cells and their applications in medical science.

Latest Patents

Among her most recent patents, Susan has focused on PDX1-positive foregut endoderm cells and methods of production. This patent discloses methodologies for creating cell cultures that contain PDX1-positive endoderm cells and outlines processes for enriching, isolating, and purifying these cells from other types. Additionally, she has developed methods for identifying differentiation factors that enhance the development of both PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells. Furthermore, her academic and practical research into human primitive ectoderm cells has led to the creation of compositions featuring human preprimitive streak and mesendoderm cells, along with methods for their production.

Career Highlights

Throughout her career, Susan has collaborated with leading organizations, notably Viacyte, Inc. and Cythera, Inc., where she has applied her expertise to drive innovative projects. Her work has led to advancements in cellular therapies and regenerative medicine, marking her as a key figure in her field.

Collaborations

Susan has had the opportunity to work alongside other esteemed professionals, such as Kevin Allen D'Amour and Alan D Agulnick. These collaborations have fostered an environment of shared knowledge and expertise, contributing to the broader scientific community.

Conclusion

In summary, Susan Eliazer is a notable inventor whose contributions to the field of cellular biology continue to shape the future of medical research. Her innovative patents and collaborations highlight her commitment to advancing science and improving health outcomes for individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.